Cell Response and Regulation (CRR)
Cell Response and Regulation (CRR)
批准号:
10152544
负责人:
Trudy Gale Oliver
金额:
$6.62万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1997
资助国家:
美国
项目状态:
未结题
起止时间:
1997-05-09 至 2025-04-30
关键词:
AddressAmerican Cancer SocietyAreaAwardBackBasic ScienceCancer BiologyCancer CenterCancer Center Support GrantCancer ControlCancer ModelCause of DeathCell Cycle StageCell DeathCell Fate ControlCell ProliferationCellsCellular biologyClinicClinicalCollaborationsDepartment of DefenseDevelopmentDiagnosticDiseaseDisseminated Malignant NeoplasmDistantDoctor of PhilosophyDrosophila genusDrug TargetingEducationEffectivenessEmbryoEnvironmentFosteringFoundationsFundingGenetically Engineered MouseGoalsGrantHumanInfrastructureInstitutesInvestigationInvestigational TherapiesJournalsMalignant NeoplasmsMediatingMetastatic toMissionModelingNeoplasm MetastasisOrganoidsPaperPathway interactionsPatientsPeer ReviewPeer Review GrantsPopulationPopulation SciencesPre-Clinical ModelPreventionPrincipal InvestigatorPublicationsPublishingRegulationResearchResearch PersonnelResistanceResource SharingSafetySchoolsScienceScientistSignal PathwaySignal TransductionSignaling MoleculeSiteSolid NeoplasmStrategic PlanningSushi DomainSystemTestingTrainingTranslatingUnited States National Institutes of HealthUniversitiesUtahWorkXenopusZebrafishbiomarker developmentcancer cellcancer preventioncancer therapycell motilitycollegeinsightinterdisciplinary collaborationinvestigator-initiated trialmalignant statemembermouse modelneoplastic cellnext generationnovelnovel strategiesnovel therapeuticspatient derived xenograft modelpatient oriented researchprognosticprogramsresponseself-renewalstemstem cellssuccesstherapy developmenttherapy resistanttranslational pipelinetumortumorigenesis
中文摘要
点击翻译按钮获取中文摘要
英文摘要
CELL RESPONSE AND REGULATION PROGRAM
ABSTRACT
The Cell Response and Regulation (CRR) Program is a basic science program at Huntsman Cancer Institute
(HCI). CRR discovery science supports the Center’s mission “to understand cancer from its beginnings” by
gaining new insight into basic mechanisms of cancer biology and providing a foundation for addressing critical
clinical issues according to HCI’s strategic plan. CRR members use scientific ingenuity and the extensive
Shared Resources provided by HCI to make new discoveries, and they collaborate with members of the
Cancer Control and Population Sciences Program and the Experimental Therapeutics Program to translate
these discoveries to the clinic and population in the areas of cancer prevention, target identification, biomarker
development, prognostics, diagnostics, and treatment development. CRR research is centered on the following
Specific Aims: 1) to elucidate mechanisms underlying cell proliferation, differentiation, and survival; 2) to
uncover mechanisms and pathways mediating tumor metastasis; and 3) to understand tumor development and
response to therapy.
CRR is comprised of 37 members, representing 15 academic departments and four schools/colleges at the
University of Utah. CRR members are well-funded, with $8.2M in peer-reviewed grant funding, of which $3.0M
(33%) is from the NCI. The remainder of the peer-reviewed funding portfolio includes grants focused on cellular
cancer mechanisms from the National Institutes of Health, the Department of Defense, Susan G. Komen
Foundation, and the American Cancer Society. Ninety-three percent of full members have current, peer-
reviewed, cancer-focused funding. In the current funding cycle, CRR members published 266 cancer-focused
papers; 14% of these represent intra-programmatic collaborations, and 41% stem from inter-programmatic
collaborations.
The synergistic aims of the CRR Program create a highly productive, collaborative, and impactful research
environment that is bolstered by the organizational capacity, infrastructure, and Shared Resources of the
Cancer Center. CRR fosters excellence in basic science discovery in cancer biology; 28% of this Program’s
papers were high-impact publications (journal impact factor >10). These discoveries directly led to six new
investigator-initiated trials in the current funding period. Program Leaders facilitate meaningful, productive,
interdisciplinary collaborations to achieve the goal of discovering and exploiting new mechanisms that underlie
tumorigenesis and metastasis. Our success in collaborative intra- and inter-programmatic science is
underscored by successful competition for nine new multi-principal investigator grants in the current funding
period.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Pro-tumor functions of neutrophils in squamous cell lung cancer
-
批准号:10643448
-
项目类别:
-
资助金额:$33.28万
-
财政年份:2022
-
负责人:Trudy Gale Oliver
-
依托单位:
Mechanisms of Arginine Deprivation in Small Cell Lung Cancer
-
批准号:10701855
-
项目类别:
-
资助金额:$38.19万
-
财政年份:2022
-
负责人:Trudy Gale Oliver
-
依托单位:
Mechanisms of Arginine Deprivation in Small Cell Lung Cancer
-
批准号:10642432
-
项目类别:
-
资助金额:$38.19万
-
财政年份:2022
-
负责人:Trudy Gale Oliver
-
依托单位:
Pro-tumor functions of neutrophils in squamous cell lung cancer
-
批准号:10576317
-
项目类别:
-
资助金额:$40.31万
-
财政年份:2022
-
负责人:Trudy Gale Oliver
-
依托单位:
Mechanisms of Arginine Deprivation in Small Cell Lung Cancer
-
批准号:10295695
-
项目类别:
-
资助金额:$36.91万
-
财政年份:2021
-
负责人:Trudy Gale Oliver
-
依托单位:
Pro-tumor functions of neutrophils in squamous cell lung cancer
-
批准号:10343793
-
项目类别:
-
资助金额:$6.66万
-
财政年份:2020
-
负责人:Trudy Gale Oliver
-
依托单位:
Identifying Mechanisms of Sox2-Driven Squamous Cell Lung Cancer
-
批准号:9272371
-
项目类别:
-
资助金额:$30.92万
-
财政年份:2014
-
负责人:Trudy Gale Oliver
-
依托单位:
Identifying Mechanisms of Sox2-Driven Squamous Cell Lung Cancer
-
批准号:9066602
-
项目类别:
-
资助金额:$30.92万
-
财政年份:2014
-
负责人:Trudy Gale Oliver
-
依托单位:
Identifying Mechanisms of Sox2-Driven Squamous Cell Lung Cancer
-
批准号:8751653
-
项目类别:
-
资助金额:$30.92万
-
财政年份:2014
-
负责人:Trudy Gale Oliver
-
依托单位:
Identifying Mechanisms of Sox2-Driven Squamous Cell Lung Cancer
-
批准号:8881129
-
项目类别:
-
资助金额:$30.92万
-
财政年份:2014
-
负责人:Trudy Gale Oliver
-
依托单位:
海外基金